{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-090197","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2025-09-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.418173+00:00","generated_at":"2026-05-17T06:00:24.167959+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Allarity Therapeutics raises ~$2.5M in private placement, with option for additional $7.5M","bullets":["Sold 1,562,500 shares at $1.60/sh and/or pre-funded warrants at $1.5999 for gross proceeds ~$2.5M.","Initial closing scheduled for Sept 23, 2025, subject to customary closing conditions.","Investor has 90-day option to purchase additional shares/warrants for up to $7.5M at then-current minimum price.","Shares and warrants issued in private placement under Section 4(a)(2); registration rights agreement filed."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-090197","json":"https://secwatch.observer/filing/0001213900-25-090197.json","markdown":"https://secwatch.observer/filing/0001213900-25-090197.md","text":"https://secwatch.observer/filing/0001213900-25-090197.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390025090197/0001213900-25-090197-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390025090197/ea0258310-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:00:24.167959+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"26eb49c505ba4c54742d7e142bdc449e637b537c","claim":"Allarity Therapeutics, Inc. issued warrant to a certain accredited investor for $0.0001 exercise price per Pre-Funded Warrant; purchase price $1.5999 per Pre-Funded Warrant.","evidence_excerpt":"the Company has agreed to issue and sell 1,562,500 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) for $1.60 per Share, and/or pre-funded warrants in (the “Pre-Funded Warrants) to purchase one share of Common Stock per Pre-Funded Warrant, at an offering price of $1.5999 per Pre-Funded Warrant (the “Purchase Price”), for gross proceeds to the Company of approximately $2.5 million, before deducting fees and expenses.","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390025090197/0001213900-25-090197-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Purchaser","value":"a certain accredited investor"},{"label":"Consideration","value":"$0.0001 exercise price per Pre-Funded Warrant; purchase price $1.5999 per Pre-Funded Warrant"}],"fact_type":"equity_issuance"},{"claim_id":"7c402df53d46ee644895a8f8adcb10b653fc3b21","claim":"Allarity Therapeutics, Inc. issued 1,562,500 shares of common stock to a certain accredited investor for $1.60 per Share, for gross proceeds of approximately $2.5 million.","evidence_excerpt":"the Initial Closing, the Company has agreed to issue and sell 1,562,500 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) for $1.60 per Share, and/or pre-funded warrants in (the “Pre-Funded Warrants) to purchase one share of Common Stock per Pre-Funded Warrant, at an offering price of $1.5999 per Pre-Funded","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390025090197/0001213900-25-090197-index.htm","confidence":0.9,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"},{"label":"Shares","value":"1,562,500 shares"},{"label":"Purchaser","value":"a certain accredited investor"},{"label":"Consideration","value":"$1.60 per Share, for gross proceeds of approximately $2.5 million"}],"fact_type":"equity_issuance"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}